These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17853162)

  • 1. Cycle control, tolerability, efficacy and acceptability of the vaginal contraceptive ring, NuvaRing: results of clinical experience in Germany.
    Brucker C; Karck U; Merkle E
    Eur J Contracept Reprod Health Care; 2008 Mar; 13(1):31-8. PubMed ID: 17853162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High acceptability and satisfaction with NuvaRing use.
    Szarewski A
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 2():31-6; discussion 37-9. PubMed ID: 12659400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with NuvaRing in daily practice in Switzerland: cycle control and acceptability among women of all reproductive ages.
    Merki-Feld GS; Hund M
    Eur J Contracept Reprod Health Care; 2007 Sep; 12(3):240-7. PubMed ID: 17763262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combined contraceptive vaginal device (NuvaRing): a comprehensive review.
    Sarkar NN
    Eur J Contracept Reprod Health Care; 2005 Jun; 10(2):73-8. PubMed ID: 16147810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combined contraceptive vaginal ring (NuvaRing): first experience in daily clinical practice in The Netherlands.
    Roumen FJ; op ten Berg MM; Hoomans EH
    Eur J Contracept Reprod Health Care; 2006 Mar; 11(1):14-22. PubMed ID: 16546812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.
    Ahrendt HJ; Nisand I; Bastianelli C; Gómez MA; Gemzell-Danielsson K; Urdl W; Karskov B; Oeyen L; Bitzer J; Page G; Milsom I
    Contraception; 2006 Dec; 74(6):451-7. PubMed ID: 17157101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contraceptive efficacy and tolerability with a novel combined contraceptive vaginal ring, NuvaRing.
    Roumen F
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 2():19-24; discussion 37-9. PubMed ID: 12659398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial.
    Oddsson K; Leifels-Fischer B; de Melo NR; Wiel-Masson D; Benedetto C; Verhoeven CH; Dieben TO
    Contraception; 2005 Mar; 71(3):176-82. PubMed ID: 15722066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label, multicentre trial to evaluate the vaginal bleeding pattern of the combined contraceptive vaginal ring NuvaRing.
    Bruni V; Pontello V; Luisi S; Petraglia F
    Eur J Obstet Gynecol Reprod Biol; 2008 Jul; 139(1):65-71. PubMed ID: 18358586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone.
    Milsom I; Lete I; Bjertnaes A; Rokstad K; Lindh I; Gruber CJ; Birkhäuser MH; Aubeny E; Knudsen T; Bastianelli C
    Hum Reprod; 2006 Sep; 21(9):2304-11. PubMed ID: 16763008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The contraceptive vaginal ring in women with renal and liver transplantation: analysis of preliminary results.
    Paternoster DM; Riboni F; Bertolino M; Garofalo G; Lazzarich E; Surico N; Stratta P
    Transplant Proc; 2010 May; 42(4):1162-5. PubMed ID: 20534250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower hormone dosage with improved cycle control.
    Vree M
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 2():25-30; discussion 37-9. PubMed ID: 12659399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Vaginal combined contraception NuvaRing in the clinical practice in the Czech Republic].
    Fait T
    Ceska Gynekol; 2009 Aug; 74(4):286-91. PubMed ID: 20564984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with the combined contraceptive vaginal ring in Switzerland, including a subgroup analysis of previous hormonal contraceptive use.
    Merki-Feld GS; Hund M
    Eur J Contracept Reprod Health Care; 2010 Dec; 15(6):413-22. PubMed ID: 21028953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acceptability and satisfaction using Quick Start with the contraceptive vaginal ring versus an oral contraceptive.
    Schafer JE; Osborne LM; Davis AR; Westhoff C
    Contraception; 2006 May; 73(5):488-92. PubMed ID: 16627032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone.
    Abu Hashim H; Alsherbini W; Bazeed M
    Contraception; 2012 Mar; 85(3):246-52. PubMed ID: 22067765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot safety and tolerability study of a nonhormonal vaginal contraceptive ring.
    Del Priore G; Malanowska-Stega J; Shalaby SW; Richman S
    J Reprod Med; 2009; 54(11-12):685-90. PubMed ID: 20120902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The contraceptive vaginal ring (NuvaRing) and hemostasis: a comparative study.
    Magnusdóttir EM; Bjarnadóttir RI; Onundarson PT; Gudmundsdóttir BR; Geirsson RT; Magnusdóttir SD; Dieben TO
    Contraception; 2004 Jun; 69(6):461-7. PubMed ID: 15157790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combined contraceptive vaginal ring, NuvaRing, and tampon co-usage.
    Verhoeven CH; Dieben TO
    Contraception; 2004 Mar; 69(3):197-9. PubMed ID: 14969666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combined contraceptive vaginal ring (NuvaRing) and endometrial histology.
    Bulten J; Grefte J; Siebers B; Dieben T
    Contraception; 2005 Nov; 72(5):362-5. PubMed ID: 16246663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.